Science

Fully Characterized Formalin-Fixed Paraffin-Embedded Tissue Blocks

publication date: Aug 13, 2021

 | 

author/source: AMS Biotechnology (Europe) Ltd

fully-characterized-formalinfixed-paraffinembedded 

AMSBIO has established an unmatched commercial biorepository and procurement network that includes a large selection of fully characterized and annotated Formalin-Fixed Paraffin-Embedded (FFPE) tissue blocks to help streamline your research.

Drawing upon decades of experience – AMSBIO is able to offer an extensive collection of frozen and paraffin-embedded (FFPE) human and animal tissue samples from normal and many diseased tissue types. All FFPE tissue blocks are processed using standard clinical procedures, under Institutional Review Board (IRB) approved protocols. Each tissue sample is pathologically verified and quality assessed by a board-licensed pathologist before being shipped with donor demographics and clinical details.

Characterized samples sets are now available and include many clinically relevant mutations and biomarkers, such as: EGFR, PD-L1, KRAS, NRAS, MSI, MMR, and BRAF. In addition, comprehensively NGS characterized FFPE solid tumour tissues suitable for assay development, genotyping and identification of new mutational hotspots. 

FFPE tissue blocks are an invaluable resource and can be supplied ready to use or can be tailored to suit your workflow and provided as slides, scrolls or array formats.

AMSBIO is a highly respected global provider of human and animal biospecimens. The company’s biorepository offers a vast array of high-quality biological materials to support your research. This includes a comprehensive range of samples from healthy, tumor and other disease states from multiple donors. AMSBIO can identify the samples to match your research demands: however, complex the donor demographics required, please contact us to find out how we can help. AMSBIO provides tissue samples in all standard formats, plus biofluids and tissue-derived products such as DNA, cDNA, total RNA, protein lysates and primary cells from a wide range of human and animal tissues.

View Product Information

About AMS Biotechnology 

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology.

Recent news from AMSBIO

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

Request your free copies HERE

Popular this Month…

Our Top 10 most popular articles this month

Today’s Picks…


Looking for a Supplier?

Search by company or by product

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Leave a Reply

Your email address will not be published. Required fields are marked *

eight  ⁄    =  two